Novel imidazolium-thiohydantoin hybrids and their Mn(iii) complexes for antimicrobial and anti-liver cancer applications

Abstract

We present the effective synthesis and structural characterization of three novel imidazolium-thiohydantoin ligands (IMTHs, 5a–c) and their Mn(iii) complexes (Mn(iii)IMTHs, 6a–c) in this study.

Bacterial Cellulose/Cellulose Imidazolium Bio-Hybrid Membranes for In Vitro and Antimicrobial Applications

“…Furthermore, the sensitivity of Gram-positive bacteria against BC/Cell-IMD is higher than that observed against Gram-negative bacteria. These results agree with other studies [ 44 , 45 ]. Therefore, these BC/Cell-IMD hydrogels are believed to have great potential for use as antimicrobial agents.…”

Dual anticancer and antibacterial activity of fluorescent naphthoimidazolium salts

“…Among therapeutic agents, imidazolium salts have been recognized for antibacterial and/or anticancer activity and their potential biomedicine applications owing to their hydrophilic nature. 36–40 These observations align with our recent research endeavor, which involved the synthesis of a naphthoimidazolium-based fluorescent chemosensor specifically designed for hypochlorite-activated antibacterial activity. 41 Our investigations have revealed that the imidazolium family, encompassing imidazolium, benzimidazolium, and halogenated imidazolium derivatives, has been extensively explored for its antibacterial and anticancer properties.…”

A New Process for the Synthesis of R‐nosylate a Key Intermediate of Nafithromycin

“…The synthetic scheme for synthesis of nafithromycin ( 5) is showed in Scheme 1. [14,15] In current manuscript, the synthesis and process optimization of stable intermediate 3 b via (R)-5-(1hydroxyethyl)-2-(pyridine-2-yl)- [1,3,4] -thiadiazole ( 14) was described. Intermediate 14 is mandatory for desired chirality of compound 3 a and 3 b.…”

“…[1] In the process of discovering new drugs, the exact orientations of enantiomeric pure drugs can interact with enzymes and reactive genes already existing in biological systems to provide the required biological activity. [2][3] Thus, regulators, companies and researchers need chiral chemicals in enantiomerically pure form in order to achieve targeted biological activity and minimized toxicological problems. [4][5][6][7][8] A unique oral and intravenous chiral lactone ketolide drug called nafithromycin (WCK 4873) (chemical name: (11S,21R)-3-decladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-{oxycarbonyl-[Z-N-[1-(5-pyridin-2-yl-1,3,4-thiadiazol-2-yl)-(S)-ethoxy]-carboxamidino]methylene}-erythromycin-A) (5) was developed by Wockhardt Ltd. to treat a variety of drug resistant common and atypical respiratory bacteria.…”